Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate

Dermatol Ther. 2022 Oct;35(10):e15736. doi: 10.1111/dth.15736. Epub 2022 Aug 8.

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by a high risk of local recurrence but a low risk of metastasis. A small subpopulation of DFSP undergoes fibrosarcomatous (FS) change, and approximately 15%-57% of cases of DFSP with FS change metastasizes, leading to a poor prognosis. In this report, a case of metastatic FS-DFSP that was successfully treated with imatinib mesylate in which the IHC staining pattern of recurrent DFSP was quantitatively analyzed in primary and metastatic DFSP areas, is described. Importantly, the recurrent area was composed of two IHC staining patterns (CD34low PD-L1high Ki67high , and CD34high PD-L1low Ki67low pattern), while the metastatic area showed a clonal pattern (CD34high PD-L1low Ki67intermediate ) in the present case. In this report, we described a case of metastatic fibrosarcomatous DFSP successfully treated with imatinib mesylate. This case suggests a subpopulation of DFSP with a favorable metastatic pattern.

Keywords: CD34; COL1A1-PDGFB fusion gene; PD-L1; fibrosarcomatous DFSP; imatinib mesylate.

Publication types

  • Case Reports

MeSH terms

  • B7-H1 Antigen
  • Dermatofibrosarcoma* / drug therapy
  • Dermatofibrosarcoma* / pathology
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Ki-67 Antigen
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • B7-H1 Antigen
  • Ki-67 Antigen
  • Imatinib Mesylate